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Abstract 
GLP-1 (glucagon-like peptide 1 (7-36) amide) plays an important role in the regulation of insulin secretion and proinsulin gene expression of 
pancreatic @ells. Patients with insulinoma tumors show uncontrolled insulin hypersecretion. This study demonstrates the molecular cloning of a 
cDNA for the GLP-1 receptor from a human insulinoma employing a I-gtl 1 cDNA library. The cloned cDNA encoded a seven transmembrane 
domain protein of 463 amino acids which showed high homology to the GLP-I receptor in normal human pancreas. Four amino acid exchanges 
were found in comparison to a receptor sequence obtained from regular pancreatic islets. When transfected transiently into COS-7 or stably into 
fibroblast CHL cells a high affinity receptor was expressed which coupled to the adenylate cyclase with normal basal CAMP and increasing intracellular 
CAMP levels under GLP-1 stimulation. The receptor accepted GLP-1 and the non-mammalian agonist exendin-4 as high affinity ligands. In transfected 
COS-7 cells, GLP-1 did not influence intracellular calcium, whereas in the stably transfected fibroblasts GLP-1 transiently increased intracellular 
calcium to a small extent. The understanding of GLP-1 receptor egulation and signal transduction will aid in the discovery of compounds that act 
as agonists of the GLP-1 receptor for potential use in the treatment of diabetes and will facilitate the understanding of its expression under normal 
and pathophysiological conditions. 
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1. Introduction 
GLP-1 (glucagon-like peptide 1 (7-36) amide) arises as 
a post-translational product of preproglucagon process- 
ing in the mammalian intestine and is released in re- 
sponse to nutrient ingestion [l-3]. It is involved in the 
regulation of glucose-dependent insulin secretion and 
proinsulin gene expression [4]. Since GLP-1 has recently 
been under consideration as a new therapeutic agent in 
the treatment of diabetes mellitus [5,6], both peptide and 
corresponding receptor, have attracted significant atten- 
tion. GLP-1 binding sites were found on human pancre- 
atic j&cells [7], cell lines from endocrine pancreas [8,9], 
gastric cells [lo], in the rat brain [ll], and in lung [12,13]. 
The action of GLP-1 is mediated by coupling to a stim- 
ulatory G-protein [14-171 which is connected to the 
adenylate cyclase pathway [ 151. Furthermore, it is known 
that the GLP-1 receptor, similar to the VIP receptor, 
undergoes important post-translational modifications, 
mainly glycosilation, which is important for its proper 
function [ 18,191. 
The molecular characterization of the GLP-1 receptor 
is interesting for several reasons. A reduced effect of the 
stimulatory insulinotropic gut hormone GLP-1 may con- 
tribute to the impaired p-cell function in diabetics. Fur- 
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thermore, the identification of a microsatellite in the 3’- 
untranslated region of the cDNA may, if polymorphic, 
be used for genetic studies aimed at linking a defect in 
this gene with disturbances of glucose homeostasis as 
was recently suggested [20,213. Furthermore, in patients 
suffering from insulinoma tumors, uncontrolled insulin 
hypersecretion occurs hypothetically involving a mu- 
tated GLP-1 receptor. This is not unlikely since a num- 
ber of human diseases can be attributed to point muta- 
tions in G protein-linked receptors [22-241 affecting 
either agonist binding, G protein-receptor interactions, 
or inproper membrane incorporation of the receptor 
[22,23,25]. 
In the present study, we have, therefore, cloned the 
GLP- 1 receptor from human insulinoma tissue and char- 
acterized its signal transduction. 
2. Experimental 
2. I. Materials 
GLP-1 (7-36) amide and the other utilized peptides (with the excep- 
tion of exendin4 and exendin (9-39) amide) were purchased from 
Saxon Biochemicals (Hannover, Germany). Exendin-4 and exendin 
(9-39) amide were synthesized as detailed before [26]. ‘%Labeled 
GLP-1 was prepared as earlier described 191. Formamide, formalde- 
hyde, 50 x Denhardt’s, and sonicated herring sperm DNA were ob- 
tained from Sigma, Deisenhofen, Germany. Nuctrap probe purification 
columns were purchased from Stratagene, La Jolla, USA. Multiprime 
labeling system, Hybond N membrane and [@P]dCTP (spec. act. 110 
TBq/mmol) were from Amersham, Braunschweig, Germany. For au- 
toradiography gels were exposed to X-OMAT AR X-ray film (Kodak) 
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at -80°C. pTEJ-8 [27] was kindly donated by Siv Hjort, Copenhagen 
(Denmark). 
2.2. Molecular cloning of the human insulinoma GLP-1 receptor cDNA 
The human insulinoma cDNA library in ;l-gt 11 vector (prepared 
according to standard procedures in cooperation with Stratagene, La 
Jolla, USA) was screened with a radioactively labeled full-length rat 
GLP-1 receptor cDNA probe (gift from B. Thorens, Lausanne, Switzer- 
land [28]) according to established protocols. Inserts of plaque-purified 
clones were released by EcoRI digest and subcloned into pBluescript 
SK +I- phagemid (Stratagene, La Jolla, USA) using Ready to Go 
Ligase (Pharmacia, Uppsala, Sweden). Nucleotide sequences were de- 
termined by the dideoxy chain termination method utilizing Sequenase 
(USB, Cleveland, USA) according to the supplier’s protocol, with prim- 
ers for T3 and T7 promoters and oligonucleotides designed according 
to the determined sequence (MWG-Biotech, Ebersberg, Germany). 
2.3. RNA Isolation and Northern blot analysis 
Total RNA from human insulinoma tissue was isolated (291 and 
poly(A)’ RNA enriched by oligo-dT column (Poly-A Quick Kit; Strat- 
agene, Heidelberg, Germany) according to the supplier’s protocol. A 
1,000 bp fragment of cDNA coding for human insulinoma GLP-1 
(7-36) amide receptor was radioactively labeled. RNA was fractionated 
on 1% agarose gels containing 2.2 M formaldehyde, transferred to 
Hybond N membranes and immobilized by UV cross-linking. RNA 
quantity was verified by reversibly staining membranes with methylene 
blue prior to hybridization. Hybridization was performed as described 
previously 1301 and migration positions of the signals were calculated 
by comparison to RNA markers. Exposure time varied from 12 h (CHL 
cells) to 14 days (RNA from human islets). Final washing was in 0.1 x 
SSC at 55°C. 
2.4. Cell transfections 
For transient expression, COS-7 cells were seeded in 100 mm coated 
dishes (Greiner, Germany) and cultured in DMEM medium supple- 
mented with 10% fetal calf serum. Cells were transfected with 10 pg of 
p72 or A9, respectively, using chloroquine and CaCl,. 24 h after trans- 
fection, the cells were detached from dishes using PBS with 1 mM 
EDTA, collected by centrifugation, reseeded into dishes or 24-well 
plates according to need for determinations of [“‘I]GLP-1 binding, 
CAMP or Ca” levels, and incubated for another 24 h at 37°C. 
Stable cell clones which selectively expressed the insulinoma GLP-1 
receptor were established in Chinese hamster lymphoblast cells (CHL) 
by transfection using the calcium phosphate precipitation method 
(CellPhect Transfection Kit; Pharmacia, Germany). Together with the 
receptor cDNA a resistence against geneticin (expression vector pTEJ- 
8; [27] and, consequently, treated cells were screened and selected for 
by their ability to resist geneticin treatment (final concentration 0.8 
mg/ml) and by their ability to specifically bind radiolabeled GLP-1 with 
high affinity. 
2.5. Receptor binding studies [9,16,17] 
Transfected cells were incubated for 30 min at 37°C with radiola- 
beled tracer (20,000 cpm) and unlabeled peptides in a final volume of 
330~1. COS cells were utilized 48 h after transfection. After incubation, 
the cell suspensions were centrifuged at 12,000 x g; the radioactivity 
retained in the pellet was determined in a y-counter. Binding in the 
presence of an excess of unlabelled GLP-1 (7-36) amide was subtracted 
in each experiment. 
2.6. Measurement of CAMP [9] 
COS-7 cells 24 h after transfection and stably transfected CHL cells 
were passaged into 24-well plates and cultured for an additional 24 h 
to confluency. lo6 cells were collected in 500 ~1 of KRB buffer; after 
a preincubation with 50 pl of IBMX for 20 min, GLP-1 was added. 
Following 10 min of incubation, cells were washed with ice-cold buffer, 
and TCA (4%) was added to stop the reaction. After diethylether 
extraction, supernatants were used for the determination of CAMP 
levels by radioimmunoassay (Immunotech, Marseille, France). 
2.7. Measurement of the cytosolic Cd’ concentration 1311 
Loading of cells (48 h after transfection) with the fluorescent calcium 
indicator fura- was performed as described [32]. Measurements of the 
tCa2+lCYt concentration and calibration of the data were performed es- 
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sentially as described previously [32,33], using a modified Krebs-Ringer 
bicarbonate buffer containing 4 mM glucose and 1.5 mM CaCl,. The 
measurements were performe: at 37°C. Since CHL cells displayed dye 
efflux during the measurements, we corrected the data as described 
previously [31] using either addition of manganese and the manganese 
chelator diethylenetrianminepenta acetic acid (DTPA) in the beginning 
and at the end of each measurement, or performing the measurements 
in the presence of 250 PM sulfinpyrazone and adding manganese and 
DTPA. 
3. Results 
3.1. RNA Isolation and Northern blot analysis 
Utilizing isolated total RNA from three human insuli- 
nomas and a 1,000 bp EcoRI fragment of the cDNA 
encoding for the human GLP-1 (7-36) amide receptor 
for Northern blot analysis, major hybridization signals 
were found at about 6 and 7 kb and less prominently at 
4.1 kb (Fig. 1). Identically sized transcripts were detected 
with RNA from normal human islets, although much 
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Fig. 1. Northern blot analysis of GLP-1 receptor expression in insulino- 
mas, regular islet cells, and transfected CHL cells. A 1,000 bp cDNA 
fragment of the insulinoma-derived GLP-1 receptor cDNA was utilized 
as probe. Total RNA from two out of three studied insulinomas (lanes 
b and c) and human islets (a) show the main transcripts of 6 and 7 kb 
and a minor signal at 4.1 kb. In transfected CHL cells stably expressing 
the GLP-1 receptor (d) the expected signal at 2 kb was detected. Arrows 
indicate migration positions of 18 and 28 S rRNA. Asterisks mark the 
weak bands of RNA from islet cells. 
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fainter signals were obtained due to the small amount of 
available RNA. Furthermore, RNA from stably trans- 
fected CHL cells was isolated and analyzed by Northern 
hybridization. A strong transcript signal of the expected 
size of approximately 2 kb was detected (Fig. 1). 
3.1. Cloning of a human insulinoma GLP-I receptor 
cDNA 
Screening of a human insulinoma R-gtll cDNA li- 
brary was performed with the rat GLP-1 receptor cDNA 
1281. Four different clones encoding partly overlapping 
regions were isolated. One cDNA, h10, was 1,700 bp in 
length and lacked approximately 27 nucleotides at the 
3’ end of the receptor coding region. Another cDNA 
clone, hl, was 900 bp in length and showed 99% homol- 
ogy to the human islet GLP-1 receptor from nucleotide 
560-1,460. To obtain a full-length human insulinoma 
GLP-1 receptor cdNA, both a HindIII-Sac1 fragment of 
h10 (coding for the 5’ end) and a SacI-EcoRI fragment 
of hl (containing the 3’ end) were subcloned into 
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Fig 2. Comparison of the deduced amino acid sequences of human 
GLP-1 (7-36) amide receptors. Top line, human insulinoma (present 
data); second line, human islets [34], third line, human islets [21], fourth 
line, human gastric tumor [35]. The predicted transmembrane s gments 
are underlined. 
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POS. INSULINOMA ISLET ISLET CASTR RAT 
(Dillon) (Thorens) TUMOR 
3 G G G G V 
4 A A A A T 
6 G G G G s 
7 P P P P L 
f I2 V L V L L J 
17 M M M M A 
33 W W W W s 
44 R R R R H 
49 s s S S F 
53 D D D D A 
55 P P P P L 
56 P P P P L 
59 E E E E D 
68 E E E E D 
76 E E E E P 
96 P P P P L 
109 
b i b 
I 
II2 H 
131 R P R R Q 
135 S S S S N 
I 136 S S W 
1 137 
S s I 
R P c P P J 
143 F F F F S 
1 151 c c A G G 1 
167 L L L L V 
I68 G G G G S 
215 S s S S G 
260 F F F 
264 W W W k 
F 
R 
267 R R R R K 
270 V V V V L 
2x2 V V V V I 
1 289 Y Y I Y Y 1 
323 I I I I V 
325 V V V V I 
330 I V I I I 
331 V I V V V 
332 V V V V I 
333 S S S S A 
3X2 I I I I V 
396 L L L L F 
400 I I I I V 
411 L L L L M 
424 H H H H R 
426 H H H H N 
443 L L L L V 
449 A A A A V 
453 M M M M V 
455 T T T T A 
460 A A A A N 
Fig. 3. Variations of amino acid composition of human GLP-1 recep- 
tors in comparison to the rat GLP-1 receptor [28,44]. Boxes indicate 
variations between the different human sequences. The more prominent 
boxes indicate the four amino acid exchanges in human insulinoma as 
compared to [21]. All positions showing variations between the rat 
sequence and at least one of the human sequences are presented. 
HindIIIIEcoRI-cut pTEJ-8 expression vector [27]. The 
plasmid was designated ~72. The product was restriction 
mapped and sequenced to confirm that it corresponded 
to human insulinoma GLP-1 receptor sequence. Simi- 
larly, the hl insert, coding for a C-terminally truncated 
receptor, was subcloned into pTEJ-8. It was utilized for 
the expression of a receptor devoid of the 9 amino acids 
at the regular C-terminus and was termed d9. 
Sequence alignment revealed that the isolated full- 
length cDNA encoded a protein of 463 amino acids 
showing > 90% homology to recently cloned human islet 
GLP-1 receptors from islets [21,34] and from the gastric 
tumor cell line HGT-1 [35] (Fig. 2). The presently re- 
ported insulinoma receptor contains seven potential 
transmembrane spanning domains and three N-linked 
glycosylation sites in the putative extracellular domains. 
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Fig. 4. (a) Displacement of [‘ZSI]GLP-l (7-36) amide binding to transiently transfected COS-7 cells by unlabeled GLP-1. COS-7 cells were transfected 
with human insulinoma GLP-1 receptor full-length cDNA in pTEJ-8. (b) Displacement of [‘251]GLP-1 (7-36) amide binding to stably transfected 
CHL cells by unlabeled GLP-1 and the endoxins. CHL cells were transfected with human insulinoma GLP-1 receptor full-length cDNA in pTEJ-8. 
Data shown are means 5 S.E.M. (n = 8) respectively. 
The human insulinoma GLP-1 receptor was not iden- 
tical to the human GLP-I receptors of normal pancreas. 
In fact, from comparing recent data [21], four amino acid 
exchanges were found (Fig. 3): at sequence position 136 
W (normal) was substituted by S (tumor); at 137 G by 
R; at 289 I by Y, at position 151, in the putative first 
transmembrane domain a conservative amino acid ex- 
change occurred (A by G). The amino acid exchanges 
were verified by sequence analysis of two or three inde- 
pendent clones, respectively. 
3.2. Specific binding of GLP-1 (7-36) amide to 
transfected cells 
To confirm that the amplified receptor cDNA was 
appropriately expressed in COS-7 cells, binding analysis 
was performed with GLP-1 (7-36) amide, and VIP. Ex- 
pression of p72 conferred specific binding of ‘251-labelled 
GLP-1 (7-36) amide upon COS-7 cells which was inhib- 
ited in a concentration-dependent manner by GLP-1. 
Analysis of the data by the Scatchard method indicated 
, the presence of a single class of binding sites with a Kd 
of 1.5 x lo-” M (n = 8) (Fig. 4a). This value lies within 
the range of reported binding properties of rat and 
human GLP-1 receptors in RIN- and COS-7 cells [36]. 
Vasoactive intestinal peptide (VIP) did not displace 
r2*I-labelled GLP-1 (7-36) amide binding. Transfection 
experiments with the truncated receptor mutant d9 did 
not reveal specific binding of GLP-1 (Fig. 4a). 
CHL cells stably transfected with p72 showed specific 
competition for binding of GLP-1, exendin4, and 
exendin (9-39) amide. The order of potency of displace- 
ment by the unlabelled peptides was exendin4 > GLP- 
1 > exendin (9-39) amide (Fig. 4b). Kd values were: 
exendin4, 2.0 x 10-‘“; GLP-1, 5.4 x lo-“; exendin (9- 
39) amide, 5.8 x 10e9 M. 
3.3. Effect of GLP-1 (7-36) amide on cyclic AMP 
concentration in transfected cells 
To verify that the cloned receptor signaled through the 
adenylyl cyclase system, the effects of GLP-1 on CAMP 
levels in extracts of transfected COS-7 cells were exam- 
ined. GLP-1 increased the CAMP content in p72 trans- 
fected cells. The CAMP level rose to 20% above basal 
levels by stimulation with lo-” M GLP-1, and to 42% 
above basal levels with 10e9 M GLP-1. There was no 
increase in CAMP in mock transfected COS-7 cells. 
In stably transfected CHL cells, intracellular genera- 
tion of CAMP was stimulated in a dose-dependent man- 
ner (Fig. 5). The CAMP level rose to 60% above basal 
levels by stimulation with IO-l2 M GLP- 1, and to 150% 
above basal levels with lo-” M GLP-1 (Fig. 5). The EC,, 
was approximately 5 x lo-‘* M. Concentrations of GLP- 
1 (7-36) amide higher than those maximally stimulating 
300 
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0 \o-13 j()-12 1o-” 10-10 10-9 10-a 
GLP-1 (M) 
Fig. 5. GLP-1 induced CAMP production in CHL cells transfected with 
the human insulinoma GLP-1 receptor. Data shown are means 
+_ S.E.M. (n = 6). 
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CAMP production showed a saturation of the stimulat- 
ing effect. There was no stimulation in CHL control cells 
(not transfected). 
3.4. Effects of GLP-I (7-36) amide on cytosolic Cd’ 
concentration in transfected cells 
In COS-7 cells transiently transfected with the insuli- 
noma GLP-1 receptor, addition of GLP-I in concentra- 
tions from lo-” to 10e6 M did not influence [Ca”],, (not 
shown). A set of experiments was performed to confirm 
the integrity of the principle calcium mobilization and 
influx mechanisms in the transfected COS-7 cells. Addi- 
tion of 1 ,uM of the intracellular calcium pump inhibitor 
thapsigargin induced a rapid rise of cytosolic calcium, 
followed by a decline to an elevated plateau (not shown). 
This demonstrated filling of intracellular calcium stores 
and presence of the capacitative calcium entry pathway 
[37] in the transfected cells. Similarly to thapsigargin, 
addition of 100 PM ATP caused a sharp peak of cy- 
tosolic calcium followed by a sustained elevation (not 
shown). ATP increases cytosolic calcium via binding to 
purinergic receptors, with subsequent opening of recep- 
tor-activated calcium channels and activation of the 
phospholipase C pathway [38]. The effect of ATP 
showed that the cytosolic calcium homeostasis in the 
transfected COS-7 cells was coupled to receptor-medi- 
ated signal transduction. 
In stably transfected CHL cells, GLP-1 produced a 
very small and transient rise of [Ca2+]cyt. low8 M GLP-1 
produced a maximal effect and raised [Ca”], by 
7.5 f 3.3 nM (n = 4), from a basal value of 121.8 f 5.4 
nM. This [Ca2+lcYt elevation peaked at approximately 
2 min after GLP-1 addition, and [Ca”], returned to the 
previous basal value within 5 min of GLP-1 addition. In 
comparison, depletion of intracellular calcium stores by 
1 ,uM thapsigargin transiently raised [Ca2+lcyt to 248 ? 20 
nM (n = 4). After chelation of extracellular calcium, a 
GLP-1 -induced rise of [Ca2+lcyt could no longer be de- 
tected. Since the thapsigargin-induced [Ca2+lcyt elevation 
was also reduced considerably, any GLP- 1 -associated 
[Ca2+]cyt elevation probably would have been too low for 
reliable detection. Therefore, it was not possible to deter- 
mine whether the GLP-l-mediated [Ca2+lcyt elevation 
was predominantly generated by calcium release from 
intracellular stores or whether it depended on influx of 
extracellular calcium. 
4. Discussion 
It is generally believed that an exact characterization 
of GLP-1 receptors will facilitate the understanding of 
the regulated expression of the receptor under normal 
and pathophysiological conditions. The present study 
evaluates the molecular and functional properties of a 
GLP-1 receptor from a human insulinoma. 
During the past years, more than 100 G protein-cou- 
pled receptor subtypes have been cloned and sequenced, 
based largely on the conservation of the primary struc- 
ture among G protein-coupled receptors, particularly 
within families, allowing the isolation of new cDNA and 
genomic clones by cross-hybridization. Very recently, a 
new subfamily of G protein-linked receptors was discov- 
ered, which, among others, comprises the receptors of 
secretin [39], vasoactive intestinal polypeptide [40], pitui- 
tary adenylyl cyclase-activating polypeptide [41], and 
glucagon [42]. This family of receptors contains seven 
potential transmembrane domains, but, interestingly, 
shows no sequence similarity with other reported G pro- 
tein-coupled receptors like the adrenergic receptors [43]. 
By transient expression of a whole rat pancreatic islet 
cDNA library into COS cells, it was recently possible to 
clone a cDNA of another member of this receptor family 
encoding for the pancreatic islet GLP-1 receptor [28]. 
This cDNA served as a template for several studies 
which revealed the molecular features of GLP-1 recep- 
tors in lung [44], the gastric tumor cell line HGT-1 [35], 
normal human islets [21,34], and now in human insuli- 
noma tissue. 
At first sight it was questionable whether human in- 
sulinomas still have the capability of expressing GLP-1 
receptors since we know that insulinoma cells show a 
variety of significant characteristics which make them 
different from normal islet B-cells, like the occurance of 
stimulus-uncoupled insulin secretion and the neo-expres- 
sion of proteins [4547]. Some data suggest that insuli- 
noma-derived p-cells even show a closer relationship to 
neuroendocrine cells than to regular /?-cells. Therefore, 
before we decided to generate a cDNA library from in- 
sulinoma RNA we prepared membrane material from an 
insulinoma which showed high tissue preservation when 
morphologically studied. These membranes were chemi- 
cally cross-linked with labeled GLP-1 to reveal the exis- 
tence of specific GLP-1 binding sites in this tumor [7]. We 
then cloned and sequenced the GLP-1 receptor utilizing 
a cDNA library derived from the above-mentioned in- 
sulinoma. 
Previously, analysis of the effects of deletion mutants, 
chimeric receptors, effects of peptides corresponding to 
portions of the receptor sequence, and antibodies di- 
rected against different cytoplasmatic regions, have been 
used to map potential sites of interaction between recep- 
tor and G protein or to analyze generally the function of 
the ligand-receptor complex [25,48,49]. The expression 
of receptors in diseased tissue provides another approach 
to correlate the structure of receptors with cell function. 
Actually, discrete mutations in several diseases, sporadic 
pituitary and thyroid tumors, McCune-Albright syn- 
drome, in adrenal and ovarian tumors result in increased 
signal transduction [25,50]. 
Analysis of the deduced amino acid sequence and 
comparison with recently published sequences from 
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human receptors revealed a high homology between 
GLP-1 receptors in normal and insulinoma tissue. Still, 
several amino acid exchanges were found and it was an 
open question whether the variations in the sequences 
found could result into functional consequences, for ex- 
ample permanent activation of a signal transduction 
pathway contributing to the clinically observed hyperin- 
sulinemia in our insulinoma patient. Previous data have 
shown that substitution of amino acid residues in the 
C-terminal segment of the third intracellular loop of 
seven transmembrane domain receptors produced 
marked agonist-independent stimulation of cellular 
phosphatidylinositol turnover [23]. Although no amino 
acid exchanges were found in this specific region, we 
functionally expressed the insulinoma GLP-1 receptor in 
COS and CHL cells to study its signal transduction prop- 
erties. 
The recombinantly expressed insulinoma GLP-1 re- 
ceptor was coupled to the adenylate cyclase system which 
was true for both transfected COS and CHL cells. Such 
coupling has been shown similarly for the GLP-1 recep- 
tor in lung [ 171, and rat insulinoma cells [15]. An abnor- 
mally increased basal CAMP level was not found. Instead 
we found a clear increase in CAMP in response to GLP-1 
stimulation. This reflects the physiological situation 
where CAMP potentiates glucose-stimulated insulin se- 
cretion [2]. 
In contrast to findings from rat insulinoma RINmSF 
cells [15] others have demonstrated in hamster insuli- 
noma HIT-15 cells that GLP-1 stimulates an increase in 
intracellular calcium through voltage-dependent calcium 
channels not associated with phospholipase C activation 
[51]. The same laboratory has proposed that calcium, not 
CAMP, is the true ‘second messenger’ for GLP-1 stimu- 
lated insulin secretion [34,51]. This proposal was based 
upon transfection studies with the cDNA of the normal 
islet GLP-1 receptor into COS cells [34]. These data sug- 
gested that a single recombinant human receptor species 
signalled through both activation of phospholipase C to 
release calcium from an intracellular pool, and activation 
of adenyl cyclase. Such coupling of a peptide receptor to 
two different second messenger systems has recently 
been shown for neuropeptide Y [52] and the cholecystok- 
inin receptor [53]. However, our present data contrast 
with those findings. Addition of GLP-1 did not produce 
any elevation of the cytosolic calcium ion concentration 
([Ca”],,) in COS-7 cells transiently transfected with the 
insulinoma GLP-1 receptor, and it generated only a very 
small and transient rise in [Cal+]+ in stably transfected 
CHL cells. These results suggest that, in contrast to the 
evident coupling to adenylate cyclase, there was no rele- 
vant interaction of the insulinoma GLP-1 receptor with 
the phospholipase C system. Due to its minimal size, the 
GLP-1 induced [Ca2+lcyt rise in stably transfected CHL 
cells was not amenable to further, detailed analysis. It 
was not possible to assess, for example, whether it in- 
volved calcium release from intracellular stores. Our 
results are in accordance with previous observations con- 
cerning GLP- 1 -associated signal transduction in endo- 
crine pancreatic /?-cells and insulin-secreting cell lines. 
GLP-1 did not elevate [Ca2’],,, at all in RINmSF rat 
insulinoma cells [15], and it raises [Ca2+lcyt in rat islet 
/%cells [54] and in HIT hamster insulinoma cells [5 l] only 
via an indirect, glucose-dependent action, probably in- 
volving CAMP-mediated activation of L-type voltage- 
dependent calcium channels. In contrast to these findings 
and our results, GLP-1 appeared to activate both adenyl- 
ate cyclase and phospholipase C in COS-7 cells tran- 
siently transfected with the rat GLP-1 receptor [32]. 
However, it has to be considered that activation of signal 
transduction pathways not normally known to be associ- 
ated with a particular receptor in vivo can be observed 
when receptors are over-expressed in a heterologous ys- 
tem [25]. This might also apply to the rat GLP-1 recep- 
tor- transfected COS-7 cells, especially in light of the lack 
of effect of GLP-1 on [Ca2+]cyt in he rat cell line RINmSF 
[15]. Therefore, the pronounced phospholipase C-medi- 
ated elevation of [Ca2’],,, by GLP-1 in COS-7 cells trans- 
fected with the rat GLP-1 receptor [32] probably does 
not represent a true fundamental difference in signal 
transduction between that receptor and the human in- 
sulinoma receptor described here. 
The recombinant insulinoma GLP-1 receptor showed 
specific binding characteristics. High affinity binding 
was only found for GLP-1 and the GLP-1 agonist 
exendin-4 and the antagonist exendin (9-39) amide [26], 
whereas vasoactive intestinal polypeptide was ineffec- 
tive. Therefore, the insulinoma GLP-1 receptor showed 
the characteristics of regular GLP-1 receptors. These 
functional data are, furthermore, supported by results 
from computer hydrophobicity plots of insulinoma and 
normal islet GLP-1 receptor amino acid sequences (La- 
sergene, DNA; London, UK) which showed only minor 
variations in the calculated hydrophobicity. 
While cloning the receptor we isolated an additional 
receptor mutant lacking the last nine cytoplasmatic 
amino acids. When this truncated receptor was expressed 
in COS cells a drastic reduction in binding ocurred which 
might suggest that the integrity of the intracellular 
C-terminal domain is important for proper binding. 
However, these studies clearly need more work. 
Considering the expected future therapeutic use of 
GLP-1 in diabetes the need for detailed knowledge of the 
binding properties and the coupling to second messenger 
pathways of the GLP-1 receptors in the different target 
tissues is important. 
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